As body weight decreases, blood vessels often function more efficiently and the heart does not need to work as hard to circulate blood throughout the body
By stabilizing the erythrocyte membrane and improving the metabolic efficiency of the cell, it reduces the rate of hemolysis (cell destruction)
How does retatrutide work in the body
Incretin-based Drugs Market Companies Few of the prominent players operating in the incretin-based drugs industry include: AstraZeneca Boehringer Ingelheim Eli Lilly and Company Merck Novo Nordisk Pfizer Sanofi Takeda Pharmaceutical Company Teva Pharmaceuticals AstraZeneca AstraZeneca holds key position in the market through its GLP-1 receptor agonist (Byetta and Bydureon) and DPP-4 inhibitors (Onglyza)
The most commonly observed include: Gastrointestinal issues such as nausea, vomiting, or diarrhea Injection site reactions (pain, redness, or itching) Hypoglycemia (low blood sugar) , especially when combined with insulin or sulfonylureas Increased heart rate in some individuals Rare allergic reactions Summary GIP/GLP-1 is a synthetic peptide analog studied in preclinical models for its interaction with GIP and GLP-1 receptors, which are central to metabolic and hormonal signaling pathways